09-14-2017 09:37 AM CET - Health & Medicine
Print

Download Global B Cell Lymphoma Market and Clinical Pipeline Insight 2022 Report

Press release from: Kuick Resarch

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:www.kuickresearch.com/report-global-b-cell-lymphoma-marke...

1. Introduction to B Cell Lymphoma
1.1 Outline
1.1.1 Non-Hodgkin’s Lymphoma
1.1.2 Hodgkin’s Lymphoma
1.2 Classification of the B Cell lymphoma
1.2.1 Diffuse Large B Cell Lymphoma
1.2.2 Follicular Lymphoma
1.2.3 Mantle Cell Lymphoma
1.2.4 Burkitt Lymphoma
1.3 Stages of B Cell Lymphoma

2. Role of B Cell Receptor for Lymphoma Development
2.1 Diffuse Large B Cell Lymphoma
2.2 Mantle Cell Lymphoma
2.3 Burkitt Lymphoma

3. Non-Hodgkin Lymphoma Risk Factors
3.1 Overview of Risk Factors
3.1.1 Infections
3.1.2 Weakened Immune System
3.1.3 Exposure to Radiation
3.1.4 Exposure to Chemicals
3.2 Causes of Non-Hodgkin Lymphoma

4. Strategies for B Cell Lymphoma Targeting Therapies
4.1 Current Strategies
4.1.1 Bruton’s Tyrosine Kinase (BTK)
4.1.2 Phosphoinositide 3-Kinase anddelta; (PI3Ks)
4.1.3 Spleen Tyrosine Kinase (SYK)
4.2 Next Generation Strategies for the Vaccine Therapy
4.2.1 Membrane Proteoliposomal Vaccine
4.2.2 Cytotoxic Therapies

5. Diagnosis of B Cell Lymphoma
5.1 Traditional Methods of Detection
5.1.1 Biopsy Method
5.1.2 Flow Cytometry
5.1.3 Molecular Genetic Tests
5.1.4 Positron Emission Tomography (PET) Scan
5.2 New Insights for Diagnosis of B Cell Lymphoma
5.2.1 Genomic Studies in the Diagnosis
5.2.2 Next Generation Sequencing
5.3 Biomarker in B Cell Malignancies
5.3.1 MicroRNA-155
5.3.2 B Cell Markers

6. Approaches for the Treatment B Cell Lymphoma
6.1 Chemotherapy
6.2 Radiation Therapy

7. Targeted Therapy Drugs for B Cell Lymphoma
7.1 Proteasome Inhibitors
7.2 Anti-CD22 Antibody Epratuzumab
7.3 Immunomodulators
7.4 Fostamatinib Disodium (Syk Inhibitor)
7.5 Membrane Target of Rapamycin (mTOR)

8. Global B Cell Lymphoma Market Overview
8.1 Current Scenario
8.2 Prevalence
8.3 B Cell Lymphoma Clinical Pipeline Overview

9. Global B Cell Lymphoma Market Dynamics
9.1 Accelerative Parameters
9.2 Challenges to the Market Growth

10. Global B Cell Lymphoma Market Future Scenario

11. Global B Cell Lymphoma Clinical Pipeline by Company and Phase
11.1 Research
11.2 Preclinical
11.3 Clinical
11.4 Phase-I
11.5 Phase-I/II
11.6 Phase-II
11.7 Phase-II/III
11.8 Phase-III
11.9 Preregistration
11.10 Registered

12. Marketed B Cell Lymphoma Clinical Insight
12.1 Rituximab (MabThera and Rituxan)
12.2 Rituximab Biosimilar (Novex)
12.3 Rituximab Biosimilar (Maball)

13. Competitive Landscape
13.1 Abbott Laboratories
13.2 Biogen Idec
13.3 Celgene Corporation
13.4 Genmab
13.5 Hetero Drugs
13.6 ImmunoGen
13.7 Incyte Corporation
13.8 mAbxience
13.9 Merck
13.10 Millennium Pharmaceuticals
13.11 Ono Pharmaceutical
13.12 Sandoz
13.13 Seattle Genetics
13.14 Xencor

Figure 1-1: Types of B Cell Lymphoma
Figure 1-2: B Cell Lymphoma Stages
Figure 2-1: B Cell Receptor in Diffuse Large B Cell Lymphoma
Figure 2-2: B Cell Receptor Signaling Pathway in Mantle Cell Lymphoma
Figure 3-1: Risk Factors Associated with B Cell Lymphoma
Figure 4-1: Bruton’s Tyrosine Kinase Pathway for Targeting
Figure 4-2: Phosphoinositide 3-Kinase anddelta; as Targeting Therapy
Figure 4-3: Spleen Tyrosine Kinase for Targeting
Figure 5-1: Traditional Methods for Diagnosis of B Cell Lymphoma
Figure 5-2: Noval Techniques for Detection
Figure 6-1: Approaches for the Treatment of B Cell Lymphoma
Figure 8-1: Global - Non-Hodgkin Lymphoma Market (US$ Billion), 2016 - 2022
Figure 8-2: Global - Hodgkin Lymphoma Market (US$ Million), 2016 - 2022
Figure 8-3: Survival Rate of Non-Hodgkin Lymphoma, % (5, 10, 15 Years)
Figure 8-4: Early Stage and Advance Stage Survival Rate, %
Figure 8-5: Estimated Cases of Non-Hodgkin Lymphoma, 100,000 Persons
Figure 8-6: US - B Cell Lymphoma Incidence
Figure 8-7: UK - Diagnosed Cases in Males and Females
Figure 8-8: UK - Mortality Cases in Males and Females
Figure 8-9: India - Incidence Rate in Males and Females
Figure 8-10: Global - B Cell Lymphoma Clinical Pipeline by Phase (%), 2017 till 2022
Figure 8-11: Global -B Cell Lymphoma Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 8-12: Global - Discontinued and Suspended B Cell Lymphoma Drugs in Clinical Pipeline (%), 2017 till 2022
Figure 8-13: Global - Discontinued and Suspended B Cell Lymphoma Drugs in Clinical Pipeline (Number), 2017 till 2022
Figure 9-1: Market Drivers of B cell Lymphoma
Figure 9-2: Challenges to the Growth of the Market

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Kuick Research
New Delhi - 110001
India
+91-11-47067990

This release was published on openPR.
News-ID: 716110 • Views: 87
More releases More releases
Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.

You can edit or delete your press release here: